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Background: Despite complete surgical resection, patients with 
stage I non–small-cell lung cancer (NSCLC) are at risk for disease 
recurrence. The impact of common oncogenic driver mutations on 
prognosis in stage I NSCLC is limited. The pure prognostic value 
of KRAS mutational status was explored in resected stage I lung 
adenocarcinoma.
Methods: Mutation status was tested in patients who had complete 
resection of stage I lung adenocarcinoma without any adjuvant 
therapy, using a multiplex polymerase chain reaction)–based assay. 
Disease-free survival (DFS) and overall survival (OS) were com-
pared between patients with KRAS-mutant (KRAS-MUT), KRAS-
MUT subtypes, and KRAS wild-type (KRAS-WT) tumors.
Results: A total of 312 patients were included in this analysis; 127 
harbored KRAS mutations and 185 had KRAS-WT tumors. When 
compared with KRAS-WT, KRAS-MUT was associated with signifi-
cantly shorter OS (hazard ratio 4.36, 95% confidence interval 2.09–
9.07; p < 0.0001) and DFS (hazard ratio 3.62, 95% confidence interval 
2.11–6.22; p < 0.0001). When stratifying KRAS-WT patients based 
on EGFR status, KRAS-MUT patients had worse OS (p = 0.0001) 
and DFS (p < 0.0001) than patients with EGFR-MUT and EGFR-
WT/KRAS-WT (WT/WT). Patients with codon 12 mutations had 
superior DFS (p = 0.0314), but there were no differences in OS com-
pared with mutations found in codons 13 and 61 (p = 0.1772). We 
observed better DFS associated with G12C/G12V mutations com-
pared with other amino acid specific KRAS mutations (p = 0.0271) 
with a trend towards improved OS (p = 0.0636). Multivariate analy-
sis identified KRAS mutation as independent predictor of worse OS 
(p = 0.001) and DFS (p < 0.0001).
Conclusion: KRAS is an independent prognostic marker in resected 
stage I lung adenocarcinoma. Differential outcomes are associated 
with codon and amino acid specific KRAS mutations.
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(J Thorac Oncol. 2014;9: 1363–1369)
Lung cancer remains one of the major causes of cancer-related mortality worldwide.1 Across all stages, the 5-year 
overall survival (OS) is less than 15%. Even stage IA and IB 
non–small-cell lung cancer (NSCLC) has a relatively poor 
prognosis with 27% to 42% of these patients dying within 
5 years.2 Surgical resection remains the cornerstone of ther-
apy for early stage NSCLC. Across all histologic subtypes 
of NSCLC, adjuvant cisplatin-based chemotherapy benefits 
patients with stage II and III disease3 and a small subset of 
patients with stage IB disease.
Advances in the genomic understanding of cancer have 
shifted the classification of NSCLC from histologic subtypes 
towards a categorization based on molecular oncogenic altera-
tions. These mutations have important prognostic and predic-
tive implications. Effective targeted treatment is available in 
the metastatic setting for subgroups of patients with onco-
genic driver alterations, such as gefitinib, erlotinib, and afa-
tinib against EGFR mutations4–6 and crizotinib against ALK 
rearrangements.7,8
The most frequent driver mutations observed in NSCLC 
affect KRAS and EGFR, occurring in 20% to 35% and 10% to 
20%, respectively, of adenocarcinoma.9–11 We recently showed 
that patients with stage I resected EGFR-mutant NSCLC have 
a better prognosis compared with the EGFR wild-type.12 Data 
on the prognostic value of KRAS mutations in completely 
resected NSCLC patients who have not received any addi-
tional treatment is limited.13 A meta-analysis of 28 studies 
explored the prognostic impact of KRAS mutations. There was 
significant heterogeneity in the studies included in the meta-
analysis, with heterogeneity in laboratory methods used to 
detect KRAS mutations, stages of lung cancer included, and 
types of treatment delivered.14 In studies that used polymerase 
chain reaction (PCR) for the detection of mutations, KRAS was 
found to be a poor prognostic marker. However, those studies 
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were limited by relatively small patient populations and the 
inclusion of multiple stages and treatments. Furthermore, 
there is controversy on the predictive role of KRAS mutations 
to chemotherapy.
Most mutations of the KRAS gene involve codon 12 
and 13. The most common amino acid specific mutations are 
G12C and G12V. Recent studies including patients with stage 
IB–III13 and stage IV15 indicate a possible predictive impact of 
different codon and amino acid (specifically G12C and G12V) 
specific mutations. The prognostic role of codon and amino 
acid specific mutation in resected stage I NSCLC has not been 
sufficiently investigated.
In this study, we investigate the prognostic role of KRAS-
mutant compared with KRAS wild-type tumors in patients 
with resected stage I lung adenocarcinoma treated with sur-
gery alone and the prognostic impact of codon and amino acid 
specific KRAS mutations.
PATIENTS AND METHODS
This is a retrospective study examining outcomes of 
patients with NSCLC based on KRAS genotype status, codon 
specific and particular point mutations of KRAS. Under an 
institutional review board-approved protocol, we reviewed 
474 patients who underwent surgical resection for lung ade-
nocarcinoma at the Massachusetts General Hospital between 
January 2008 and November 2011. We included patients in 
our study who had pathologic stage I NSCLC (AJCC version 
7), surgical resection with curative intent and who had testing 
for known oncogenic driver mutations. Patients with stage II, 
III, and IV disease, tumor histology other than adenocarci-
noma, absent or failed genotyping, those who received adju-
vant or neoadjuvant systemic therapy of any sort, and patients 
without adequate follow-up documentation or imaging were 
excluded.
Genotyping
Genetic testing of oncogenic drivers in NSCLC in a 
Clinical Laboratory Improvement Amendments (CLIA)-
certified institutional laboratory has been clinically available 
at our institution since 2004. Initially, testing was performed 
using direct sequencing upon provider request based on clini-
cal and demographic patient characteristics. Since 2008, and 
most consistently in 2009, all resected NSCLC have under-
gone routine molecular testing using the allele-specific, 
PCR-based SNaPshot platform to detect frequent mutations 
of common oncogenic driver genes and additional testing of 
known genetic alterations using FISH. The SNaPshot testing 
used for the detection of these mutations is a highly sensi-
tive and specific method. The average sensitivity for muta-
tions tested with SNaPshot ranges between 94 and 99%, 
with an average sensitivity of 95%, and a specificity of more 
than 95%.16
Covariates and Data Collection
For all patients included in the study, baseline patient 
characteristics were collected, including age, sex, self-iden-
tified race/ethnicity (White, Black, Asian, Hispanic), Zubrod 
Performance Status, smoking history, pulmonary function 
testing (forced expiratory volume in 1 second and DLCO) and 
medical comorbidities, including hypertension (HTN), coro-
nary artery disease (CAD), congestive heart failure, diabetes 
mellitus (DM), and chronic obstructive pulmonary disease 
(COPD). Smoking status was characterized as: (1) never-
smokers, less than 100 cigarettes in their lifetime, (2) former 
smokers, quit more than 1 year before diagnosis, and (3) cur-
rent smokers, ongoing smoking habit or quit less than 1 year 
before diagnosis.
Tumor stage was categorized according to the American 
Joint Committee on Cancer Staging Manual version 7. T and 
N staging was based primarily on the results from mediasti-
noscopy, lymph node dissection, and surgical resection, with 
additional clinical information abstracted from fluorode-
oxyglucose positron emission tomography (PET), computed 
tomography (CT), and magnetic resonance imaging. Date and 
type of surgery (lobectomy, wedge resection, or segmentec-
tomy) were recorded. Mutational status of all tested genes 
derived from SNaPshot testing, and when available ALK-
FISH and ROS1-FISH, were collected.
Patients were assessed for recurrence, disease-free 
survival (DFS) and OS. Recurrence was defined as radio-
graphic evidence of cancer relapse on surveillance imaging 
(CT, CT-PET, or magnetic resonance imaging) and/or patho-
logic tumor evidence on a biopsy. Recurrence rate (RR) was 
the fraction of recurrent patients among the total. DFS was 
defined as the time from surgery until recurrence or death. OS 
was defined as time from surgery until death. Patients were 
censored at their last known alive date. Date of death was 
obtained from the electronic medical record and confirmed on 
the Social Security Death Index (SSDI) Web site.
Statistical Analysis
Differences between covariates, recurrence, and death 
rates in patients with KRAS-mutant, EGFR-mutant, and wild-
type tumors were analyzed using Fisher’s exact test, Freeman–
Halton extension of Fisher’s exact test, and t test. DFS and 
OS were analyzed using the Kaplan–Meier method, and a 
log-rank test was used to compare the KRAS-mutant, EGFR-
mutant, and wild-type group. Cox multivariate analysis was 
performed with five variables (mutation status, tumor size, 
smoking status, sex, and procedure) to test for independent 
markers of DFS and OS. Mutation status, procedure, and sex 
were entered into the Cox proportional hazard model as class 
variables. Analyses were performed using statistical software, 
SAS version 9.4.
RESULTS
Patient Population
Of 474 patients who underwent surgical resection for 
lung adenocarcinoma at Massachusetts General Hospital 
between 2008 and 2011, a total of 312 were included in 
this study, and follow-up information was collected through 
December 2013. Reasons for exclusion of patients and 
comparison of basic characteristics between included and 
excluded patients are summarized in Supplemental Figure 
1 and Supplemental Table 1 (Supplemental Digital Content, 
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http://links.lww.com/JTO/A653). All included patients had 
completely resected stage I lung adenocarcinomas and testing 
for genetic alterations. None of the included patients received 
adjuvant therapy of any sort (including radiation therapy, 
conventional chemotherapy, or targeted cancer therapy). 
Characteristics of patients included in this study are sum-
marized in Table 1. One hundred twenty-seven patients had 
tumors with a KRAS mutation (KRAS-MUT) and 185 were 
KRAS wild-type (KRAS-WT). There were no significant dif-
ferences between both cohorts with respect to sex distribution, 
age, race/ethnicity, tumor size, type of procedure performed, 
functional status, and medical comorbidities. Significantly 
more patients were former or current smokers in the KRAS-
MUT group, whereas the KRAS-WT group included more 
never-smokers (p < 0.00001). Accordingly, the number of 
pack years was higher in the KRAS-MUT group (p = 0.0001).
Genotype Results
Genotyping was performed using the SNaPshot assay. 
A total of 220 mutations with known involvement in carci-
nogenesis were detected (Fig. 1). Additional gene rearrange-
ments were detected using FISH in four patients. Genetic 
alterations include 127 KRAS mutations (40.7%), 61 EGFR 
mutations (19.6%), and 32 other gene mutations (10.3%). Two 
patients had a double mutation of EGFR (T790M and L858R, 
and T790M and exon 19 deletion). Twelve of 127 KRAS-MUT 
patients (9.5%) had an additional mutation involving TP53  
(n = 5), PIK3CA (n = 5), BRAF (n = 1), and CTNNB1 (n = 1) 
(Fig. 1). In 185 KRAS-WT patients, additional genetic altera-
tions were found in HER2 (n = 5), TP53 (n = 2), PIK3CA (n = 4), 
BRAF (n = 3), ALK (n = 3), ROS1 (n = 1), CTNNB1 (n = 1), 
and IDH1 (n = 1). Consistent with recent reports, we found 
alterations of HER2,17 ALK,18 and ROS119 to occur mutually 
exclusive from KRAS or EGFR mutations.
Impact of KRAS Mutations on OS and DFS
The median follow-up time was 36 months. There were 
90 events, including 59 disease recurrences and 31 deaths 
during the observation period. In the KRAS-MUT group, 22 
of 127 patients (17.3%) died compared with 9 of 185 (4.9%) 
in the KRAS-WT group (p = 0.0001). OS was significantly 
shorter in the KRAS-MUT group with a Hazard ratio (HR) of 
4.36 (95% confidence interval [CI] 2.09–9.07; p < 0.0001). 
The estimated 3-year OS was 84% versus 95% in the KRAS-
MUT compared with the KRAS-WT group (Fig. 2). The RR 
was 37/127 (29.1%) in patients with KRAS-MUT and 22/185 
TABLE 1.  Baseline Data of Included Patients with KRAS-
Mutant (KRAS-MUT) and KRAS Wild-Type (KRAS-WT) NSCLC
KRAS-MUT KRAS-WT p Value
Total N 127 (41%) 185 (59%)
Male, n (%) 44 (35) 62 (20) 0.9
Age 67 ± 10 68 ± 11 0.42
Tumor size 0.26
  <2 cm 64 (50%) 109 (59%)
  2–3 cm 36 (28%) 39 (21%)
  >3 cm 27 (21%) 37 (20%)
Race/ethnicity, n (%)
  White 123 (97) 172 (93) 0.2
  Asian 3 (2) 11 (6) 0.17
  Hispanic 1 (1) 2 (1) 1
Procedure, n (%) 0.38
  Lobectomy 72 (57) 115 (62)
  Wedge 45 (35) 52 (28)
  Segmentectomy 10 (8) 18 (10)
Smoking, n (%) 0.00001
  Never 9 (7) 52 (28)
  Past 81 (64) 100 (54)
  Current 37 (29) 33 (18)
  Pack years 40 ± 26 26 ± 26 0.0001
  Zubrod 0.37 ± 0.5 0.34 ± 0.52 0.61
Comorbidities, n (%)
  HTN 63 (50) 90 (49) 0.91
  COPD 27 (21) 25 (14) 0.09
  CAD 25 (20) 27 (15) 0.28
  CHF 5 (4) 3 (2) 0.28
  DM 19 (15) 19 (10) 0.22
  Steroid use 2 (2) 3 (2) 1
Pulm function tests
  FEV
1
81 ± 20 89 ± 22 0.0012
  DLCO 71 ± 21 76 ± 24 0.06
HTN, hypertension; COPD, chronic obstructive pulmonary disease; CAD, coronary 
artery disease; CHF, congestive heart failure; DM, diabetes mellitus; PFTs, pulmonary 
functions tests; FEV
1
, forced expiratory volume in 1 second; DLCO, diffusing capacity.
FIGURE 1.  Genetic alterations in 312 patients with resected 
stage I lung adenocarcinoma. Relative frequency of KRAS, 
EGFR, and other mutations with a breakdown of specific 
alterations in each group and the number of co-mutations 
that occurred in KRAS-mutant tumors. (*Both T790M muta-
tions occurred in tumors with an additional EGFR mutation, 
one with L858R and one with exon 19 deletion.)
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(11.9%) in the KRAS-WT group (p = 0.0002). DFS was sig-
nificantly shorter in the KRAS-MUT group compared with 
patients with KRAS-WT tumors (HR 3.62, 95% CI 2.11–6.22; 
p < 0.0001) (Fig. 2). The estimated 3-year DFS in KRAS-MUT 
versus KRAS-WT was 64% and 89%, respectively.
In a Cox regression model using KRAS mutation sta-
tus, tumor size, smoking status, sex, and surgical procedure as 
independent variables, only KRAS mutation status was found 
to be an independent predictor for OS (HR 3.87, 95% CI 
1.73–8.66; p = 0.001) and DFS (HR 3.29, 95% CI 1.87–5.76, 
p < 0.0001) (Table 2). We recently reported that EGFR-mutant 
(EGFR-MUT) NSCLC is associated with better OS and DFS 
compared with EGFR wild-type (EGFR-WT).12 In the cur-
rent study, we confirmed these findings. We show that KRAS-
MUT was associated with worse OS and DFS compared with 
patients who are EGFR-MUT or wild-type for both KRAS 
and EGFR (WT/WT) (Fig. 3). In a multivariate analysis with 
KRAS-MUT, EGFR-MUT, and WT/WT patients, the mutation 
status was found to be the only independent predictor for OS 
(HR 2.84, 95% CI 1.01–6.3; p = 0.04) and DFS (HR 1.69, 
95% CI 1.24–2.29; p = 0.0008) (Table 3).
Effect of Codon and Amino Acid Specific 
KRAS Mutations on OS and DFS
Among those with KRAS mutations, codon 12 mutations 
were found in 109 patients (86%), codon 13 in 11 patients 
(9%), and codon 61 in seven patients (5%). Among all KRAS-
MUT tumors, G12C and G12V accounted for 62% (n = 79) 
(Fig. 1A). Compared with codon 13 and codon 61 muta-
tions, codon 12 mutations were associated with better DFS 
(p = 0.0314), whereas no significant difference in OS (p = 0.1772) 
was found (Fig. 4A, B). The median DFS in the patient group 
with codon 13 or codon 61 mutation was 25.7 months (95% 
CI 19.83 months to 38.5 months). We observed significantly 
longer DFS in patients with G12C or G12V mutations com-
pared with other KRAS mutations (p = 0.0272). The median 
DFS in the patient group with mutations other than G12C or 
G12V was 38.5 months (95% CI 26 months to 38.5 months). 
There was also a trend towards better OS in patients with G12C 
or G12V compared with other KRAS mutations (p = 0.0636) 
(Fig. 4C, D).
DISCUSSION AND CONCLUSION
The characterization of genomic alterations has led 
to a shift from sole histologic classification of NSCLC 
towards a molecular genetic categorization with distinct 
clinicopathologic correlates and predictors for treatment 
response to targeted cancer therapies. The most common 
oncogenic driver mutation in NSCLC involves KRAS. Our 
analysis of 312 patients identifies KRAS mutation status as 
an independent marker for poor prognosis in completely 
resected stage I NSCLC. Patients with KRAS-MUT had 
significantly worse OS (p < 0.0001) and DFS (p < 0.0001). 
In the KRAS-MUT group, the 3-year OS and DFS were 
84% versus 95% and 64% versus 89% compared with 
KRAS-WT patients. In a multivariate analysis, KRAS muta-
tion status was the only independent predictor for OS (p 
= 0.001) and DFS (p < 0.0001). The prognostic effect of 
KRAS remained statistically significant in the univariate 
FIGURE 2. A, Overall survival (OS) and (B) Disease-free 
survival (DFS) in patients with KRAS-mutant versus KRAS wild-
type tumors.
TABLE 2.  Multivariate Analysis for Overall Survival (OS) 
and Disease-Free Survival (DFS) Using KRAS Mutation Status, 
Tumor Size, Smoking Status, Sex, and Performed Procedure 
as Independent Variables in Patients with KRAS-Mutant vs. 
KRAS Wild-Type Tumors
Covariate HR 95% CI p Value
OS Mutation status 3.87 1.7309–8.6566 0.0010
Tumor size 1.45 0.9541–2.2033 0.08
Gender 0.73 0.3378–1.5910 0.43
Smoking status 1.49 0.8339–2.6525 0.18
Procedure 1.50 0.8845–2.5539 0.13
PFS Mutation status 3.29 1.8751–5.7629 <0.0001
Tumor size 1.24 0.9020–1.7019 0.19
Gender 1.08 0.6417–1.8314 0.76
Smoking status 1.33 0.8727–2.0126 0.19
Procedure 1.27 0.8496–1.8899 0.25
CI, confidence interval.
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and multivariate analyses when stratifying the KRAS-WT 
by EGFR mutation status. As shown recently, resected 
EGFR-MUT NSCLC is associated with better prognosis 
compared with EGFR-WT disease.12 In conjunction with 
the results presented in this study, we provide further sup-
port that KRAS-MUT and EGFR-MUT disease are clini-
cally distinct subsets of NSCLC.
The prognostic impact of KRAS mutations in NSCLC 
has been a subject of controversy in prior studies. A meta-
analysis of 28 studies across all stages revealed that patients 
with KRAS mutations had a worse prognosis.14 This effect was 
found in studies in which PCR was used as method to detect 
RAS mutations. However, this meta-analysis was limited by 
multiple factors. There was significant heterogeneity among 
the studies with respect to disease stages, histology, treatment 
modalities, and methods by which mutations were detected. 
Furthermore, there was no sufficient confirmation of the find-
ings in a well-designed multivariate analysis.
In contrast to our findings, two recently published stud-
ies did not show a significant prognostic/predictive impact of 
mutated KRAS in NSCLC.13,20 When compared with our anal-
ysis, some substantial differences in the design and patient 
populations may explain the different results. The first analy-
sis by D’Angelo et al. is a retrospective study of 1118 patients 
with resected stage I to III NSCLC, including 277 with 
KRAS-mutant and 222 with EGFR-mutant tumors. Across 
all included stages, patients with KRAS wild-type tumors had 
longer median OS compared with KRAS-mutant tumors (6.6 
years versus 6.1 years); however, this result did not reach sta-
tistical significance (p = 0.38). EGFR-mutant tumors were 
associated with significantly better OS (p < 0.0001). A sig-
nificant portion of patients (~26%) received cytotoxic therapy 
and 84 of 222 (~38%) EGFR-mutant tumors were treated with 
adjuvant/neoadjuvant tyrosine kinase inhibitors. Shepherd 
and colleagues reported a pooled analysis of four clinical tri-
als that investigated adjuvant chemotherapy versus observa-
tion for stage IB to III NSCLC, including adenocarcinoma 
and squamous cell carcinoma histology. Of the 1543 included 
patients, 300 had KRAS mutations. The authors found no over-
all prognostic or predictive impact of KRAS. However, despite 
the large size of the trials included in this pooled analysis, 
there was considerable variability of the individual studies 
with regards to the prognostic and predictive impact of KRAS. 
While patients with KRAS mutations derived some benefit 
from adjuvant therapy in the ANITA trial, they did poorer 
in JBR.10 and Cancer and Leukemia Group B-9633.21 This 
emphasizes the difficulty and further need for subcategoriz-
ing KRAS-mutant tumors. Furthermore, higher stages (II and 
III) were over-represented in the KRAS-WT group, which may 
have resulted in worse outcomes in the comparator group and 
thereby blunted the prognostic effect of KRAS. A subset of 
KRAS-MUT patients who carried codon 13 mutations and 
accounted for 8% of all KRAS mutations had significantly 
worse outcomes.
The major differences between both studies and our 
analysis are the inclusion of higher stages (II and III) and 
the use of adjuvant/neoadjuvant cytotoxic and/or targeted 
therapies. By limiting the analysis to stage IA and IB (tumors 
FIGURE 3. A, Overall survival (OS) and (B) Disease-free sur-
vival (DFS) in patients with KRAS-mutant, EGFR-mutant, and 
KRAS wild-type/EGFR wild-type NSCLC (WT/WT).
TABLE 3.  Multivariate Analysis for Overall Survival (OS) 
and Disease-Free Survival (DFS) Using KRAS Mutation Status, 
Tumor Size, Smoking Status, Sex, and Performed Procedure as 
Independent Variables in Patients with KRAS-Mutant, EGFR-
Mutant, and KRAS Wild-Type/EGFR Wild-Type Tumors (WT/WT)
Covariate HR 95% CI p Value
OS Mutation status 2.82 1.0139–6.305 0.04
Tumor size 1.44 0.9424–2.205 0.09
Gender 0.72 0.3279–1.561 0.40
Smoking status 1.30 0.7194–2.362 0.38
Procedure 1.70 0.4744–6.063 0.43
DFS Mutation status 1.69 1.2442–2.2862 0.0008
Tumor size 1.27 0.9283–1.7392 0.14
Gender 1.13 0.6681–1.9061 0.65
Smoking status 1.48 0.9927–2.2161 0.05
Procedure 1.32 0.8930–1.9634 0.16
CI, confidence interval; HR, hazard ratio.
1368 Copyright © 2014 by the International Association for the Study of Lung Cancer
Izar et al. Journal of Thoracic Oncology ®  •  Volume 9, Number 9, September 2014
≤3 cm) and excluding patients who received any additional 
therapy our analysis provides a window on the purely prog-
nostic impact of KRAS mutations. Furthermore, differences 
in the patient populations may further contribute to the dis-
tinctive results: our analysis included more current smokers in 
the KRAS-MUT group compared with D’Angelo et al. (29% 
versus 19%) and more never-smokers in the KRAS-WT group 
compared with Shepherd et al. (28% versus 12%), which 
could explain worse outcomes in the KRAS-MUT group and 
better outcomes in the KRAS-WT group and therefore amplify 
the differences between both groups. As shown in the analy-
sis by Shepherd et al., codon 13 mutations were associated 
with worse outcomes. This is consistent with our analysis (see 
below). While these patients only accounted for 8% in the 
analysis above, a larger portion of codon 13 and codon 61 
mutations (14% of our KRAS-mutant patients) were present 
in our analysis and further contribute to poorer outcomes in 
the KRAS-MUT group.
It has been proposed that codon-specific KRAS and par-
ticular amino acid mutations could have prognostic and pre-
dictive role in advanced15,22 and stage IB–III NSCLC.13 In this 
study, we characterized the impact of codon and amino acid 
substitution specific prognostic impact of KRAS in resected 
stage I (IA and IB) lung adenocarcinoma. Consistent with 
prior studies, we found KRAS mutations most frequently 
located on codon 12 (86%), followed by codon 13 (9%), and 
codon 61 (5%). The most frequent amino acid mutations were 
G12C and G12V, accounting for ~62% of cases. We observed 
worse DFS in the patient group with codon 13 or codon 61 
mutations compared with those with codon 12. This is consis-
tent with a recent report that found worse survival associated 
with codon 13 compared with codon 12 mutations.13 However, 
due to the relatively low frequency of codon 13 and codon 61 
mutations conclusions regarding their prognostic significance 
have to be made in larger patient populations.
We observed better DFS in patients with G12C or G12V 
mutations compared with other KRAS mutations (p = 0.0271) 
with a trend towards better OS (p = 0.0636). This is in contrast 
to observations made in a small subset of patients enrolled 
in the Biomarker-integrated Approaches of Targeted Therapy 
for Lung Cancer Elimination (BATTLE) trial.15 The authors 
investigated DFS in 43 patients stratified by specific KRAS 
FIGURE 4. A, Overall survival (OS) and (B) Disease-free survival (DFS) in KRAS codon 12 mutant tumors compared with other 
KRAS mutations. C, Overall survival (OS) and (D) DFS (disease-free survival) in G12V or G12C mutant tumors compared with 
other KRAS mutations.
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mutations (G12C or G12V versus other KRAS mutations and 
KRAS-WT) and found the worst DFS in patients with G12C or 
G12V mutations, particularly in patients receiving sorafenib, 
a multi-tyrosine kinase inhibitor. The study was limited by 
very small sample size, and these patients were fundamentally 
different from the patient population we investigated in this 
study. The patients included in the BATTLE trial differ sig-
nificantly from the population we have investigated in the cur-
rent study. Patients in the BATTLE trial had stage IV disease 
and had undergone multiple lines of cytotoxic and/or targeted 
cancer therapies. In conclusion, it is possible that G12C and 
G12V mutations are associated with better prognosis com-
pared with other KRAS mutations, while they may be markers 
for poor treatment response in patients with advanced disease.
Our study has inherent limitations, such as the retrospec-
tive design and its single center patient cohort. Although no 
major differences between patients included and excluded in 
this analysis were found (Supplemental Table 1, Supplemental 
Digital Content, http://links.lww.com/JTO/A653), 107 of the 
excluded patients had no genotyping, which may have intro-
duced an enrichment of other patient characteristics, such as 
never-smoker status, to the final study population. We acknowl-
edge that the proportion of KRAS-mutant tumors (~40%) in our 
study cohort is somewhat higher than the published literature 
(20–37%).11,13,15,23 The majority of these studies report testing 
only for codon-12KRAS mutations. Testing of less common 
mutations found on codon 13 and codon 61 contributes to a 
significant increase in the detection of KRAS mutations. Taken 
together, these mutations accounted for 14% of KRAS-mutant 
tumors in our study population and may therefore contribute 
to the higher frequency of KRAS-mutant tumors observed in 
this study. Furthermore, the potential impact of co-mutations 
or other mutations on the KRAS pathway, including mutations 
in genes such as LKB1, BRAF, NRAS, MEK, or AKT, will need 
to be investigated in the future.
In conclusion, we identify KRAS as independent prognos-
tic marker in resected stage I NSCLC in a large and homog-
enously treated patient cohort. The impact of KRAS mutations 
remained significant when stratifying the control group based on 
EGFR mutation status. We provide further support that KRAS- 
and EGFR-mutant tumors are distinct subsets of NSCLC. 
Particular KRAS codon-specific (codon 13 and 61) and amino 
acid–specific mutations (G12C or G12V) are associated with 
differential outcomes compared with other KRAS mutations. 
These findings provide further support for routine genetic testing 
of resected lung cancer. As new therapies targeting downstream 
RAS pathways such as PI3K/AKT/mTOR are developed for 
advanced NSCLC, their efficacy should be further evaluated in 
resected KRAS-mutant stage I lung adenocarcinomas by virtue 
of worse outcome compared with KRAS wild-type disease.
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